AGLE News and Press, Aeglea BioTherapeutics Inc. From 04/12/23

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives PR Newswire Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction...

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire AUSTIN, Texas , March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of...

Aeglea BioTherapeutics press release ( NASDAQ: AGLE ): FY GAAP EPS of -$0.99 beats by $0.03 . Revenue of $2.33M (-87.6% Y/Y) beats by $0.1M . As of December 31, 2022, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of $57.3 millio...

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates PR Newswire Jeffrey Goldberg , experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief...

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill , M.B.A., ...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzy...

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer PR Newswire AUSTIN, Texas , Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme...

Aeglea BioTherapeutics ( NASDAQ: AGLE ) said on Tuesday it had appointed Linda Neuman as the chief medical officer. Neuman's appointment is an internal promotion from her previous role as Aeglea's senior vice president of clinical development. Before Aeglea, Neum...

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer PR Newswire AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation o...